Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference
26 Julio 2023 - 3:05PM
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in
minimally invasive treatments for severe lung disease, today
announced the company will present at the upcoming Canaccord
Genuity 43rd Annual Growth Conference in Boston. Management is
scheduled to present on Wednesday, August 9, 2023, at 12:00 PM PT /
3:00 PM ET.
A live and archived webcast of the presentation
will be available on the “Investors” section of the Pulmonx website
at https://investors.pulmonx.com/.
About Pulmonx CorporationPulmonx Corporation
(Nasdaq: LUNG) is a global leader in minimally invasive treatments
for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve,
Chartis® Pulmonary Assessment System and StratX® Lung Analysis
Platform are designed to assess and treat patients with severe
emphysema/COPD who despite medical management are still profoundly
symptomatic. Pulmonx received FDA pre-market approval to
commercialize the Zephyr Valve following its designation as a
“breakthrough device.” The Zephyr Valve is commercially available
in more than 25 countries, with over 100,000 valves used to treat
more than 25,000 patients. For more information on the Zephyr
Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered
trademarks of Pulmonx Corporation.
ContactBrian JohnstonGilmartin
Groupinvestors@pulmonx.com
Pulmonx (NASDAQ:LUNG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Pulmonx (NASDAQ:LUNG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024